Research and Markets: United States Pharmaceuticals and Healthcare Report Q4 2010: 1.8% Growth Expected in 2011

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/8421bd/united_states_phar) has announced the addition of the "United States Pharmaceuticals and Healthcare Report Q4 2010" report to their offering.

The United States Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on the United States' pharmaceuticals and healthcare industry.

The US pharmaceutical market remains ranks first, both regionally and globally, in BMIs Pharmaceuticals & Healthcare Business Environment Ratings update for Q410. This placement is a reflection of its massive potential and limited risks relative to other markets. The country's pharmaceutical spending reached almost US$306bn in 2009.

While the rate of spending will be modest over the coming five years we forecast a compound annual growth rate (CAGR) of just 1.76%, due to a combination of factors that include patent expirations and pending healthcare reform that will increase the role of the state in healthcare funding the market will reach US$334bn in value at consumer prices by 2014, thus remaining unparalleled globally.

In the meantime, the country's regulatory environment, already considered model, will continue to focus on drug safety. The US Food and Drug Administration (FDA) recently launched a new scheme under which it has started posting the results of safety evaluations of recently-approved drugs and vaccines online.

Similarly, it entered a memorandum of understanding (MOU) with Drugs.com for the establishment of a cooperative public education programme, which it is hoped will strengthen access to the agency's consumer-health information. Additionally, in August 2010, major consumer, physician and chemical manufacturing groups pledged their support to a proposed bill that intends to protect drug supply in the US by authorising the US FDA to safeguard pharmaceutical supply chains.

As always, the past quarter has witnessed a number of activities in the US pharmaceutical marketplace. US major Johnson & Johnson (J&J) has withdrawn 21 lots of medicines, including Tylenol (acetaminophen) for children and adults and several OTC drugs such as Benadryl (diphenhydramine) and Motrin (ibuprofen). As the company does not expect most of those medicines to be available before the end of 2010, Swiss Novartis is planning to fill the gap its new liquid children's medicine, Triaminic (phenylpropanolamine) Fever Reducer/Pain Reliever, backed by the US$1.5mn marketing programme.

Market development will also be shaped by the wider economic climate, given that the healthcare reform strategy envisages expanding state insurance coverage for the poor and that insurers will be banned from excluding people with pre-existing medical conditions which may lead to changes in their pricing strategies. We continue to project 2.8% real GDP growth this year and 1.8% in 2011, as headline growth has been shown to be losing momentum, going from 5.0% in Q409 to 3.7% in Q110 to 2.4% in Q210. The labour market remains very weak, which will dampen consumption growth, including purchases of medicines, especially as reports suggest that some patients already choose not to fill their prescriptions due to costs.

The number of medical services used by insured members of the US population has also been falling, with insurers, lab-testing companies, hospitals and doctors reporting that patient visits, drug prescriptions and procedures were all down in Q210 compared with Q209.

Key Topics Covered:

SWOT Analysis

  • US Pharmaceuticals And Healthcare Industry SWOT
  • United States Political SWOT
  • United States Economic SWOT
  • United States Business Environment SWOT

Pharmaceutical Business Environment Ratings

  • Rewards
  • Risks

US - Market Summary

  • Regulatory Regime
  • Innovative Drug Regulations
  • CDER Approval Times For Priority And Standard NDAs And New BLAs*
  • CDER NME and New BLA Approvals: May 2009 - April 2010
  • Generic Drug Regulations
  • CDER Approval Times For Original Generic Drugs
  • First-time ANDA Generic Drug Approvals
  • Biosimilar Regulations
  • OTC Medicine Regulations
  • Medical Device Regulations
  • US FDA Medical Device Approvals May 2009-April 2010
  • Promotion Regulations
  • Intellectual Property (IP) Regulations
  • PhRMA Special 301 Submissions 2010
  • Pricing & Reimbursement Environment

Industry Developments

  • Industry Forecast Scenario
  • Overall Market Forecast
  • Key Growth Factors Industry
  • Macroeconomic Forecast Scenario
  • Prescription Drug Market Forecast
  • Top 10 Therapeutic Classes By Sales (US$bn)
  • Top 10 Therapeutic Classes By Dispensed Prescriptions (mn)
  • Patented Product Market Forecast
  • Generic Drug Market Forecast
  • OTC Medicine Market Forecast
  • Medical Device Market Forecast
  • Pharmaceutical Trade Forecast
  • Key Risks to BMIs Forecast Scenario
  • Competitive Landscape
  • Research-Based Industry
  • Top 10 Companies By US Prescription Sales (US$bn)
  • Top 10 Branded Drugs By Retail Sales 2008
  • Research-Based Industry Quarterly Developments
  • Generic Drugmakers
  • Top 10 Companies By US Dispensed Prescriptions (mn)
  • Top 10 Generic Drugs By Retail Sales 2008
  • Generic Drug Industry Quarterly Developments
  • Drug Distribution Sector
  • Pharmacy Retail Sector
  • US Dispensed Prescription Drug Distribution By Channel Distribution Value (US$bn)
  • US Dispensed Prescription Drug Distribution By Channel Distribution Volume (mn)

Company Profiles

  • Leading Indigenous Players
  • Leading Foreign Players

Companies Mentioned:

  • Pfizer
  • Merck & Co
  • Eli Lilly
  • Amgen
  • Watson Pharmaceuticals
  • GlaxoSmithKline (GSK)

For more information visit http://www.researchandmarkets.com/research/8421bd/united_states_phar



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:   United States  North America  New York

INDUSTRY KEYWORDS:   Health  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

After Purdue’s record opioid settlement, more deals could be on the way. But that doesn’t mean all defendants are prepared to go quietly.

Now in their third quarter on the market, Gilead's own Epclusa and Harvoni generics have together grabbed more than 20% of the U.S. hep C market.

Purdue is seeking bankruptcy after inking a $10 billion-plus opioid settlement with thousands of cities and counties, plus two dozen states.